GLP-1 and Dentistry: Oral Health Risks Every Dentist Should Know

GLP-1 receptor agonists are increasingly common among dental patients, and understanding how they work — and what they mean for oral health — is now an essential part of taking a thorough medical and dental history. This guide explains what GLP-1 drugs do, the oral health risks they carry, and the questions dentists should be asking patients who use them.

What Are GLP-1 Receptor Agonists?

GLP-1 receptor agonists are prescription medications available in the UK that mimic the natural gut hormone glucagon-like peptide (GLP-1) to regulate blood sugar, slow stomach emptying and reduce appetite. Although best known as a treatment for obesity and weight loss, they are also used to manage blood glucose in Type 2 diabetes and to lower the risk of heart attack and stroke in high-risk patients.

GLP-1 receptor agonists work by:

• Imitating the gut hormone glucagon-like peptide released after eating.
• Reducing the rate of stomach emptying.
• Stimulating insulin release, which lowers blood sugar.
• Signalling fullness to the brain through fast nerve impulses and slower gut hormones — stomach stretching triggers signals to the hypothalamus that switch off hunger.

Common GLP-1 Medications Used in the UK

• Tirzepatide (Mounjaro) — research suggests it is the most effective for weight loss and blood sugar control; given by weekly subcutaneous injection.
• Semaglutide (Ozempic, Wegovy) — given by weekly injection or daily tablet.
• Liraglutide (Saxenda) — given by daily injection.
• Exenatide (Byetta) — one of the earliest formulations, given by twice-daily injection or as an extended-release, once-weekly injection.

While GLP-1 receptor agonists imitate glucagon, some newer formulations, such as Mounjaro, also act on a second hormone, GIP (Glucose-Dependent Insulinotropic Polypeptide), which is involved in appetite and blood sugar control.

These drugs are licensed by the MHRA (Medicines and Healthcare products Regulatory Agency) for weight loss and diabetic control alongside reduced calorie intake and exercise, but they are not licensed for weight loss for aesthetic or cosmetic purposes.

Side Effects Dentists Should Be Aware Of

• Nausea and vomiting.
• Diarrhoea and constipation.
• Bloating and abdominal pain.
• Headaches, dizziness, weakness and mood changes.

Side effects are generally mild, but can occasionally be more pronounced, leading to severe dehydration and hospital admission. Rarely, GLP-1 drugs can cause acute pancreatitis with serious outcomes.

Women of child-bearing age should either avoid these drugs or use appropriate contraception, as some animal studies have shown harm to the foetus, although no human studies have been reported to date. Patients using the contraceptive pill should also use a barrier method for four weeks after starting a GLP-1 drug, since these medications can reduce oral contraceptive effectiveness. Reduced appetite is an intended effect of treatment, but patients should be monitored to ensure calorie intake does not fall too low.

Why GLP-1 Use Matters for Dental History-Taking

As part of taking a general medical and dental history, dentists should ask specific questions of any patient prescribed a GLP-1 receptor agonist — including how much weight has been lost and whether any complications have arisen from use of the drug. In particular, consideration should be given to:

• Use in Type 2 diabetes management, to assess and mitigate any risk of hypoglycaemia.
• Any past history of eating disorders associated with use of the medication.
• Any dental complications of weight loss, such as a loss of fit of dental prostheses.
• Delayed stomach emptying, which can increase the risk of vomiting and pulmonary aspiration if sedation or anaesthesia is being considered.

How GLP-1 Drugs Affect Oral Health

GLP-1 receptor agonists do not damage teeth directly. However, they can drive oral changes that promote secondary oral health risks and dental damage. Key risks include:

• Dry mouth (xerostomia) — associated with reduced fluid intake, resulting in smaller volumes of more viscous saliva and reduced protection against bacteria.
• Enamel erosion — delayed stomach emptying may precipitate acid reflux or vomiting; gastric acid coating the teeth causes mineral loss and erosion.
• Increased dental caries risk — an acidic, dry mouth environment allows caries-producing bacteria to thrive.
• Disturbed oral sensation — some patients report a metallic taste, or sour and burning symptoms linked to dry mouth.

Patients identified as using any GLP-1 receptor agonist should be counselled about this increased dental risk and advised to maintain fluid intake and practise careful oral hygiene, including regular brushing with a fluoride toothpaste.

The Bigger Picture: GLP-1 Drugs in Practice

GLP-1 drugs have become an important part of managing the complications of diabetes and excessive weight gain, and represent a genuine game-changer for many patients. They typically produce a 15–22.5% reduction in weight over an average of seventy weeks, with tirzepatide reported as the most effective option.* An estimated 1.5 million people in the UK currently use them to reduce hunger, manage blood sugar and support eating less. Unlike many medicines, one of their most notable effects is patients simply feeling well during use — likely reflecting the benefits of stable blood sugar, reduced inflammation, psychological relief from reduced food cravings, and the extra energy and lifted mood that can come from being free of the daily strain of food-related challenges.

Frequently Asked Questions

Do GLP-1 drugs like Ozempic damage teeth?

Not directly. GLP-1 receptor agonists do not damage teeth themselves, but they can cause dry mouth, acid reflux and enamel erosion, which raise the risk of dental caries and other secondary oral health problems.

What should a dentist ask a patient taking Ozempic, Wegovy or Mounjaro?

Dentists should ask about the amount of weight lost, any complications experienced, whether the drug is being used to manage Type 2 diabetes (to assess hypoglycaemia risk), any history of eating disorders, and whether weight loss has affected the fit of any dental prostheses.

Can GLP-1 medications cause dry mouth?

Yes. Reduced fluid intake associated with GLP-1 use can lead to xerostomia (dry mouth), producing smaller amounts of thicker saliva and reducing the mouth’s natural protection against bacteria.

Is dental sedation safe for patients taking GLP-1 drugs?

It requires extra caution. Because GLP-1 drugs delay stomach emptying, patients may be at increased risk of vomiting and pulmonary aspiration during sedation or general anaesthesia, so this should be assessed before treatment.

What are the main GLP-1 receptor agonist drugs used in the UK?

The main options are tirzepatide (Mounjaro), semaglutide (Ozempic and Wegovy), liraglutide (Saxenda) and exenatide (Byetta), varying by dosing schedule and administration method.

How much weight loss do GLP-1 drugs typically produce?

Published studies suggest an average weight reduction of around 15–22.5% over roughly seventy weeks, with tirzepatide generally reported as the most effective option.

Paul Lambden

* Average results from publicly available studies at time of writing, September 2026.